CBT-I Therapy Targets Both Sleep and Alzheimer's Amyloid in Older Adults
A completed RCT tests whether treating insomnia with CBT-I can improve cognition and slow amyloid buildup in adults aged 60–85.
Summary
The SIESTA trial enrolled 200 older adults with insomnia to test whether a six-week Cognitive Behavioral Therapy for Insomnia program could improve cognitive function and slow the accumulation of beta-amyloid — a key Alzheimer's hallmark. Participants were randomly assigned to CBT-I or sleep and lifestyle education. A subgroup of 50 underwent PET brain imaging at baseline and one year later to directly measure amyloid changes. The study recognizes that poor sleep accelerates amyloid deposition, and that treating insomnia may offer a modifiable pathway to reduce Alzheimer's risk. Completed in April 2025, this trial represents one of the first randomized efforts to link a behavioral sleep intervention directly to amyloid biology in at-risk older adults.
Detailed Summary
Sleep disturbance and Alzheimer's disease share a dangerous feedback loop. Poor sleep accelerates the accumulation of beta-amyloid (Aβ), a toxic protein that aggregates in the brain years before dementia symptoms emerge. Conversely, Aβ itself disrupts sleep architecture. If treating insomnia can interrupt this cycle, behavioral sleep therapy could become a scalable, low-risk tool for Alzheimer's prevention.
The SIESTA trial, sponsored by the University of Kansas Medical Center, set out to rigorously test this hypothesis. Two hundred adults aged 60–85 with insomnia symptoms were randomly assigned to either a structured six-week CBT-I program — the gold-standard behavioral treatment for insomnia — or a sleep and lifestyle education control condition. The primary aims were to compare cognitive outcomes between groups and to examine how changes in sleep quality correlated with changes in cognitive performance.
A particularly innovative aspect of the design involved a 50-participant neuroimaging substudy. These individuals underwent Florbetapir PET scans, which allow direct quantification of amyloid plaques in living brains, at baseline and again one year after the intervention. This provides a rare opportunity to determine whether a behavioral intervention can measurably slow amyloid accumulation over time — a question with profound implications for prevention.
The trial completed enrollment of 200 participants and reached its final completion date in April 2025. Full results have not yet been published in peer-reviewed form as of this summary. If CBT-I is shown to reduce amyloid burden, it would validate sleep as a therapeutic target in Alzheimer's prevention and support routine insomnia screening in aging populations.
Caveats include the relatively short six-week intervention window, the modest subsample for PET imaging, and the fact that full results remain unpublished. The summary here is based on the trial registration abstract alone.
Key Findings
- CBT-I was tested as a potential tool to slow beta-amyloid accumulation in adults aged 60–85 with insomnia.
- PET amyloid imaging in 50 participants allows direct measurement of brain plaque changes one year post-intervention.
- Trial compared CBT-I to sleep and lifestyle education across 200 randomized participants.
- Cognitive function was assessed as a primary outcome alongside sleep quality measures.
- Trial completed April 2025; peer-reviewed results are not yet publicly available.
Methodology
Randomized controlled trial enrolling 200 adults aged 60–85 with insomnia symptoms, assigned to six-week CBT-I or sleep education control. A 50-participant substudy used Florbetapir PET imaging at baseline and one-year follow-up to quantify amyloid deposition changes. Phase designation is not applicable, reflecting its behavioral rather than pharmacological design.
Study Limitations
This summary is based on the abstract and trial registration only, as full results are not yet published. The PET imaging substudy includes only 50 of 200 participants, limiting statistical power for the amyloid endpoint. The six-week intervention window may be insufficient to produce detectable amyloid changes measurable at one year.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.